HLA-dependent tumour development: A role for tumour associate macrophages?

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Marchesi, Maddalena ^a,c   Andersson, Emilia ^a   Villabona, Lisa ^a   Seliger, Barbara ^b   Lundqvist, Andreas ^a   Kiessling, Rolf ^a   Masucci, Giuseppe V ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DECOY RECEPTOR 3; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA B ASSOCIATED TRANSCRIPT 3; HLA C ANTIGEN; HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; KILL CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CARCINOGENESIS; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; GENE EXPRESSION; HUMAN; LYMPHOCYTE FUNCTION; MACROPHAGE; NATURAL KILLER CELL; POLARIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; TH2 CELL; TUMOR ASSOCIATE MACROPHAGE; TUMOR CELL; TUMOR DEVELOPMENT; TUMOR MICROENVIRONMENT; UPREGULATION;

HLA ANTIGENS; HUMANS; MACROPHAGES; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84884968894     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-247     Document Type: Article

References (148)

1. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896. 10.1038/ni.1937, 20856220.
2. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122. 10.1182/blood-2005-01-0428, 16269622.
3. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000, 164:6166-6173.
4. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555. 10.1016/S1471-4906(02)02302-5, 12401408.
5. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, Pitman N, Mirchandani A, Rana B, van Rooijen N, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009, 183:6469-6477. 10.4049/jimmunol.0901575, 19841166.
6. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217. 10.1016/j.ccr.2005.02.013, 15766659.
7. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
8. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196:254-265. 10.1002/path.1027, 11857487.
9. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237. 10.1016/j.coi.2010.01.009, 20144856.
10. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012, 122:787-795. 10.1172/JCI59643, 3287223, 22378047.
11. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010, 70:5728-5739. 10.1158/0008-5472.CAN-09-4672, 20570887.
12. Bak SP, Alonso A, Turk MJ, Berwin B. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol 2008, 46:258-268. 10.1016/j.molimm.2008.08.266, 2613193, 18824264.
13. Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 2000, 164:762-767.
14. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009, 86:1065-1073. 10.1189/jlb.0609385, 19741157.
15. Chen J, Li G, Meng H, Fan Y, Song Y, Wang S, Zhu F, Guo C, Zhang L, Shi Y. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother 2012, 61:101-108. 10.1007/s00262-011-1094-3, 21853301.
16. Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, Conejo-Garcia JR. CD277 Is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget 2010, 1:329-338. 2992324,2992324, 21113407.
17. Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 2012, 61:249-254. 10.1007/s00262-011-1153-9, 22120755.
18. Schaefer MR, Williams M, Kulpa DA, Blakely PK, Yaffee AQ, Collins KL. A novel trafficking signal within the HLA-C cytoplasmic tail allows regulated expression upon differentiation of macrophages. J Immunol 2008, 180:7804-7817. 2440697, 18523244.
19. McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med 1995, 181:2085-2095. 10.1084/jem.181.6.2085, 2192076, 7760000.
20. Neisig A, Melief CJ, Neefjes J. Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. J Immunol 1998, 160:171-179.
21. Demaria S, Schwab R, Bushkin Y. The origin and fate of beta 2m-free MHC class I molecules induced on activated T cells. Cell Immunol 1992, 142:103-113. 10.1016/0008-8749(92)90272-Q, 1586951.
22. Martayan A, Fraioli R, Giorda E, Setini A, Ciccarelli G, Delfino L, Ferrara GB, Giacomini P. Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. Br J Cancer 1999, 80:639-649. 10.1038/sj.bjc.6690405, 2362293, 10360639.
23. Schnabl E, Stockinger H, Majdic O, Gaugitsch H, Lindley IJ, Maurer D, Hajek-Rosenmayr A, Knapp W. Activated human T lymphocytes express MHC class I heavy chains not associated with beta 2-microglobulin. J Exp Med 1990, 171:1431-1442. 10.1084/jem.171.5.1431, 2187879, 2139695.
24. Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, Koopman LA, Valter MM, Angelisova P, Horejsi V, Strominger JL. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci U S A 2002, 99:16180-16185. 10.1073/pnas.212643199, 138585, 12454284.
25. Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, Markel G, Goldman-Wohl D, Yagel S, Horejsi V, Levy O, et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 2003, 171:1343-1351.
26. Zilberman S, Schenowitz C, Agaugue S, Benoit F, Riteau B, Rouzier R, Carosella ED, Rouas-Freiss N, Menier C. HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment. Eur J Immunol 2012, 42:1599-1608. 10.1002/eji.201141761, 22678912.
27. Cochran JR, Cameron TO, Stern LJ. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity 2000, 12:241-250. 10.1016/S1074-7613(00)80177-6, 10755611.
28. Shiroishi M, Kohda D, Maenaka K. Preparation and crystallization of the disulfide-linked HLA-G dimer. Biochim Biophys Acta 2006, 1764:985-988. 10.1016/j.bbapap.2005.10.006, 16290109.
29. Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, Arase H, Tsumoto K, Kumagai I, Kohda D, Maenaka K. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 2006, 281:10439-10447. 10.1074/jbc.M512305200, 16455647.
30. Apps R, Gardner L, Sharkey AM, Holmes N, Moffett A. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol 2007, 37:1924-1937. 10.1002/eji.200737089, 2699429, 17549736.
31. Howangyin KY, Loustau M, Wu J, Alegre E, Daouya M, Caumartin J, Sousa S, Horuzsko A, Carosella ED, Lemaoult J. Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors. Cell Mol Life Sci 2012, 69:4041-4049.
32. Pangault C, Le Friec G, Caulet-Maugendre S, Lena H, Amiot L, Guilloux V, Onno M, Fauchet R. Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Hum Immunol 2002, 63:83-90. 10.1016/S0198-8859(01)00373-1, 11821155.
33. Ibrahim EC, Aractingi S, Allory Y, Borrini F, Dupuy A, Duvillard P, Carosella ED, Avril MF, Paul P. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer 2004, 108:243-250. 10.1002/ijc.11456, 14639610.
34. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002, 196:266-274. 10.1002/path.1039, 11857488.
35. Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, Prigione I, Pistoia V. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 2007, 67:6433-6441. 10.1158/0008-5472.CAN-06-4588, 17616704.
36. Kren L, Muckova K, Lzicarova E, Sova M, Vybihal V, Svoboda T, Fadrus P, Smrcka M, Slaby O, Lakomy R, et al. Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity?. J Neuroimmunol 2010, 220:131-135. 10.1016/j.jneuroim.2010.01.014, 20167379.
37. Schutt P, Schutt B, Switala M, Bauer S, Stamatis G, Opalka B, Eberhardt W, Schuler M, Horn PA, Rebmann V. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol 2010, 71:489-495. 10.1016/j.humimm.2010.02.015, 20156510.
38. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 2001, 92:369-376. 10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U, 11466692.
39. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003, 13:371-377. 10.1016/S1044-579X(03)00028-2, 14708717.
40. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: Are they clinically relevant?. Semin Cancer Biol 2007, 17:469-479. 10.1016/j.semcancer.2007.07.004, 2200630, 17825579.
41. Mach P, Blecharz P, Basta P, Marianowski P, Skret-Magierlo J, Kojs Z, Grabiec M, Wicherek L. Differences in the soluble HLA-G blood serum concentration levels in patients with ovarian cancer and ovarian and deep endometriosis. Am J Reprod Immunol 2010, 63:387-395. 10.1111/j.1600-0897.2009.00806.x, 20146732.
42. Leleu X, Le Friec G, Facon T, Amiot L, Fauchet R, Hennache B, Coiteux V, Yakoub-Agha I, Dubucquoi S, Avet-Loiseau H, et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res 2005, 11:7297-7303. 10.1158/1078-0432.CCR-05-0456, 16243800.
43. Amiot L, Le Friec G, Sebti Y, Drenou B, Pangault C, Guilloux V, Leleu X, Bernard M, Facon T, Fauchet R. HLA-G and lymphoproliferative disorders. Semin Cancer Biol 2003, 13:379-385. 10.1016/S1044-579X(03)00029-4, 14708718.
44. Cao M, Yie SM, Liu J, Ye SR, Xia D, Gao E. Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens 2011, 78:120-128. 10.1111/j.1399-0039.2011.01716.x, 21726203.
45. Morandi F, Scaruffi P, Gallo F, Stigliani S, Moretti S, Bonassi S, Gambini C, Mazzocco K, Fardin P, Haupt R, et al. Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins. PLoS One 2012, 7:e29922. 10.1371/journal.pone.0029922, 3253802, 22253825.
46. Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1998, 8:1-10.
47. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998, 160:4951-4960.
48. Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou JP, Charreau B. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2007, 109:2806-2814.
49. Benevolo M, Mottolese M, Tremante E, Rollo F, Diodoro MG, Ercolani C, Sperduti I, Lo Monaco E, Cosimelli M, Giacomini P. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med 2011, 9:184. 10.1186/1479-5876-9-184, 3219584, 22032294.
50. Silva TG, Crispim JC, Miranda FA, Hassumi MK, de Mello JM, Simoes RT, Souto F, Soares EG, Donadi EA, Soares CP. Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness. Histol Histopathol 2011, 26:1487-1497.
51. Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H, van Hall T. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci U S A 2011, 108:10656-10661. 10.1073/pnas.1100354108, 3127933, 21670276.
52. de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, Liefers GJ, van den Elsen PJ, van de Velde CJ, Kuppen PJ. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010, 185:7452-7459. 10.4049/jimmunol.1002629, 21057081.
53. Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C, et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol 2008, 32:633-641.
54. Derre L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 2006, 177:3100-3107.
55. Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol 2005, 64:523-528.
56. Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F. Analysis of HLA-E expression in human tumors. Immunogenetics 2003, 54:767-775.
57. Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, Pistillo MP. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol 2005, 66:1-12.
58. Oliveira CC, van Veelen PA, Querido B, de Ru A, Sluijter M, Laban S, Drijfhout JW, van der Burg SH, Offringa R, van Hall T. The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med 2010, 207:207-221. 10.1084/jem.20091429, 2812552, 20038604.
59. Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P. Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia 2011, 13:822-830. 3182274, 21969815.
60. Allard M, Oger R, Vignard V, Percier JM, Fregni G, Perier A, Caignard A, Charreau B, Bernardeau K, Khammari A, et al. Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One 2011, 6:e21118. 10.1371/journal.pone.0021118, 3119680, 21712991.
61. Mouillot G, Marcou C, Zidi I, Guillard C, Sangrouber D, Carosella ED, Moreau P. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 2007, 68:277-285. 10.1016/j.humimm.2006.10.016, 17400064.
62. Lee N, Geraghty DE. HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol 2003, 171:5264-5271.
63. Lee N, Ishitani A, Geraghty DE. HLA-F is a surface marker on activated lymphocytes. Eur J Immunol 2010, 40:2308-2318. 10.1002/eji.201040348, 20865824.
64. Lin A, Zhang X, Ruan YY, Wang Q, Zhou WJ, Yan WH. HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. Lung Cancer 2011, 74:504-509. 10.1016/j.lungcan.2011.04.006, 21561677.
65. Zhang X, Lin A, Zhang JG, Bao WG, Xu DP, Ruan YY, Yan WH. Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma. Int J Cancer 2013, 132:82-89. 10.1002/ijc.27621, 22544725.
66. Noguchi K, Isogai M, Kuwada E, Noguchi A, Goto S, Egawa K. Detection of anti-HLA-F antibodies in sera from cancer patients. Anticancer Res 2004, 24:3387-3392.
67. Boyle LH, Gillingham AK, Munro S, Trowsdale J. Selective export of HLA-F by its cytoplasmic tail. J Immunol 2006, 176:6464-6472.
68. Wainwright SD, Biro PA, Holmes CH. HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib protein with a restricted expression pattern. J Immunol 2000, 164:319-328.
69. Goodridge JP, Burian A, Lee N, Geraghty DE. HLA-F complex without peptide binds to MHC class I protein in the open conformer form. J Immunol 2010, 184:6199-6208. 10.4049/jimmunol.1000078, 3777411, 20483783.
70. Lepin EJM, Bastin JM, Allan DSJ, Roncador G, Braud VM, Mason DY, Merwe PA, McMichael AJ, Bell JI, Powis SH, O'Callaghan CA. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. European J Immunol 2000, 30:3552-3561.
71. Sloane DE, Tedla N, Awoniyi M, MacGlashan DW, Borges L, Austen KF, Arm JP. Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition. Blood 2004, 104:2832-2839. 10.1182/blood-2004-01-0268, 15242876.
72. Brown D, Trowsdale J, Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 2004, 64:215-225. 10.1111/j.0001-2815.2004.00290.x, 15304001.
73. Lichterfeld M, Kavanagh DG, Williams KL, Moza B, Mui SK, Miura T, Sivamurthy R, Allgaier R, Pereyra F, Trocha A, et al. A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med 2007, 204:2813-2824. 10.1084/jem.20061865, 2118510, 18025130.
74. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999, 11:603-613. 10.1016/S1074-7613(00)80135-1, 10591185.
75. Willcox BE, Thomas LM, Bjorkman PJ. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol 2003, 4:913-919.
76. Shiroishi M, Kajikawa M, Kuroki K, Ose T, Kohda D, Maenaka K. Crystal structure of the human monocyte-activating receptor, " group 2" leukocyte Ig-like receptor A5 (LILRA5/LIR9/ILT11). J Biol Chem 2006, 281:19536-19544. 10.1074/jbc.M603076200, 16675463.
77. Shiroishi M, Kuroki K, Rasubala L, Tsumoto K, Kumagai I, Kurimoto E, Kato K, Kohda D, Maenaka K. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A 2006, 103:16412-16417. 10.1073/pnas.0605228103, 1637596, 17056715.
78. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol 2001, 167:5543-5547.
79. Jones DC, Kosmoliaptsis V, Apps R, Lapaque N, Smith I, Kono A, Chang C, Boyle LH, Taylor CJ, Trowsdale J, Allen RL. HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. J Immunol 2011, 186:2990-2997. 10.4049/jimmunol.1003078, 21270408.
80. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003, 100:8856-8861. 10.1073/pnas.1431057100, 166403, 12853576.
81. Huang J, Goedert JJ, Sundberg EJ, Cung TD, Burke PS, Martin MP, Preiss L, Lifson J, Lichterfeld M, Carrington M, Yu XG. HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. J Exp Med 2009, 206:2959-2966. 10.1084/jem.20091386, 2806456, 20008523.
82. Mamegano K, Kuroki K, Miyashita R, Kusaoi M, Kobayashi S, Matsuta K, Maenaka K, Colonna M, Ozaki S, Hashimoto H, et al. Association of LILRA2 (ILT1, LIR7) splice site polymorphism with systemic lupus erythematosus and microscopic polyangiitis. Genes Immun 2008, 9:214-223. 10.1038/gene.2008.5, 18273033.
83. Thomas R, Matthias T, Witte T. Leukocyte immunoglobulin-like receptors as new players in autoimmunity. Clin Rev Allergy Immunol 2010, 38:159-162. 10.1007/s12016-009-8148-8, 19548123.
84. Candore G, Lio D, Colonna Romano G, Caruso C. Pathogenesis of autoimmune diseases associated with 8.1 Ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 2002, 1:29-35. 10.1016/S1568-9972(01)00004-0, 12849055.
85. Ryu M, Chen Y, Qi J, Liu J, Fan Z, Nam G, Shi Y, Cheng H, Gao GF. LILRA3 Binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1/LILRB2: structural evidence. PLoS One 2011, 6:e19245. 10.1371/journal.pone.0019245, 3084784, 21559424.
86. Nowak J, Kalinka-Warzocha E, Juszczynski P, Bilinski P, Mika-Witkowska R, Zajko M, Bienvenu J, Coiffier B, Salles G, Warzocha K. Association of human leukocyte antigen ancestral haplotype 8.1 With adverse outcome of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 2007, 46:500-507. 10.1002/gcc.20436, 17311253.
87. Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B, et al. The common scandinavian human leucocyte antigen ancestral haplotype 62.1 As prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 2009, 58:1599-1608. 10.1007/s00262-009-0669-8, 19214504.
88. Chen Y, Gao F, Chu F, Peng H, Zong L, Liu Y, Tien P, Gao GF. Crystal structure of myeloid cell activating receptor leukocyte Ig-like receptor A2 (LILRA2/ILT1/LIR-7) domain swapped dimer: molecular basis for its non-binding to MHC complexes. J Mol Biol 2009, 386:841-853. 10.1016/j.jmb.2009.01.006, 19230061.
89. Lee DJ, Sieling PA, Ochoa MT, Krutzik SR, Guo B, Hernandez M, Rea TH, Cheng G, Colonna M, Modlin RL. LILRA2 Activation inhibits dendritic cell differentiation and antigen presentation to T cells. J Immunol 2007, 179:8128-8136. 2650749, 18056355.
90. Arosa FA, Santos SG, Powis SJ. Open conformers: the hidden face of MHC-I molecules. Trends Immunol 2007, 28:115-123. 10.1016/j.it.2007.01.002, 17261379.
91. Masuda A, Nakamura A, Maeda T, Sakamoto Y, Takai T. Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation. J Exp Med 2007, 204:907-920. 10.1084/jem.20060631, 2118540, 17420263.
92. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A 1993, 90:12000-12004. 10.1073/pnas.90.24.12000, 48113, 8265660.
93. Anfossi N, Doisne JM, Peyrat MA, Ugolini S, Bonnaud O, Bossy D, Pitard V, Merville P, Moreau JF, Delfraissy JF, et al. Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J Immunol 2004, 173:7223-7229.
94. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008, 224:70-84. 10.1111/j.1600-065X.2008.00660.x, 2587243, 18759921.
95. Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I, Long EO. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006, 4:e9. 10.1371/journal.pbio.0040009, 1318474, 16366734.
96. Rajagopalan S, Long EO. KIR2DL4 (CD158d): an activation receptor for HLA-G. Front Immunol 2012, 3:258. 3422731, 22934097.
97. Miah SM, Hughes TL, Campbell KS. KIR2DL4 differentially signals downstream functions in human NK cells through distinct structural modules. J Immunol 2008, 180:2922-2932.
98. Li C, Houser BL, Nicotra ML, Strominger JL. HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci U S A 2009, 106:5767-5772. 10.1073/pnas.0901173106, 2667005, 19304799.
99. Lanier LL. NK cell recognition. Annu Rev Immunol 2005, 23:225-274. 10.1146/annurev.immunol.23.021704.115526, 15771571.
100. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J 1999, 18:4250-4260. 10.1093/emboj/18.15.4250, 1171501, 10428963.
101. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799. 10.1038/35869, 9486650.
102. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998, 187:813-818. 10.1084/jem.187.5.813, 2212178, 9480992.
103. Krawczyk M, Seguin-Estevez Q, Leimgruber E, Sperisen P, Schmid C, Bucher P, Reith W. Identification of CIITA regulated genetic module dedicated for antigen presentation. PLoS Genet 2008, 4:e1000058. 10.1371/journal.pgen.1000058, 2278383, 18437201.
104. Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW, Chen NJ, Lin CH, Hsieh SL. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004, 75:486-494.
105. Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL. Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 2005, 175:5135-5145.
106. Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett 2000, 160:89-97. 10.1016/S0304-3835(00)00567-X, 11098089.
107. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bahr M, Ohgaki H, Ashkenazi A, Weller M. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 2001, 61:2759-2765.
108. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703. 10.1038/25387, 9872321.
109. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, Caskey CT. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A 2000, 97:1230-1235. 10.1073/pnas.97.3.1230, 15578, 10655513.
110. Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 2008, 10:1049-1056. 2546583, 18813347.
111. Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, Chen L, Hsieh SL. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 2002, 168:4846-4853.
112. Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, Hsieh SL. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 2008, 111:5054-5063. 10.1182/blood-2007-12-130609, 18349319.
113. You RI, Chang YC, Chen PM, Wang WS, Hsu TL, Yang CY, Lee CT, Hsieh SL. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 2008, 111:1480-1488.
114. Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ, Chou TY, Tarng DC, Hsieh SL. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol 2012, 188:2464-2471. 10.4049/jimmunol.1101101, 22287720.
115. Kamper N, Franken S, Temme S, Koch S, Bieber T, Koch N. Gamma-interferon-regulated chaperone governs human lymphocyte antigen class II expression. FASEB J 2012, 26:104-116. 10.1096/fj.11-189670, 21940994.
116. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer 2009, 125:367-373. 10.1002/ijc.24401, 19378341.
117. Hessa T, Sharma A, Mariappan M, Eshleman HD, Gutierrez E, Hegde RS. Protein targeting and degradation are coupled for elimination of mislocalized proteins. Nature 2011, 475:394-397. 10.1038/nature10181, 3150218, 21743475.
118. Sasaki T, Gan EC, Wakeham A, Kornbluth S, Mak TW, Okada H. HLA-B-associated transcript 3 (Bat3)/scythe is essential for p300-mediated acetylation of p53. Genes Dev 2007, 21:848-861. 10.1101/gad.1534107, 1838535, 17403783.
119. Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, PoggevonStrandmann E. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One 2008, 3:e3377. 10.1371/journal.pone.0003377, 2566590, 18852879.
120. Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Boll B, Simhadri VL, Borchmann P, et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007, 27:965-974. 10.1016/j.immuni.2007.10.010, 18055229.
121. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, Qureshi M, Dong Q, Gu X, Chen WV, Spitz MR, Eisen T, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008, 40:1407-1409. 10.1038/ng.273, 2695928, 18978787.
122. McIntire RH, Morales PJ, Petroff MG, Colonna M, Hunt JS. Recombinant HLA-G5 and -G6 drive U937 myelomonocytic cell production of TGF-beta1. J Leukoc Biol 2004, 76:1220-1228. 10.1189/jlb.0604337, 15459235.
123. Ashcroft GS. Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect 1999, 1:1275-1282. 10.1016/S1286-4579(99)00257-9, 10611755.
124. Zhang W, Liang S, Wu J, Horuzsko A. Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation 2008, 86:1125-1134. 10.1097/TP.0b013e318186fccd, 2668611, 18946352.
125. Agaugue S, Carosella ED, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 2011, 117:7021-7031. 10.1182/blood-2010-07-294389, 21482709.
126. Allan DS, Colonna M, Lanier LL, Churakova TD, Abrams JS, Ellis SA, McMichael AJ, Braud VM. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med 1999, 189:1149-1156. 10.1084/jem.189.7.1149, 2193000, 10190906.
127. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 1998, 160:3096-3100.
128. Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. Proc Natl Acad Sci U S A 2008, 105:8357-8362. 10.1073/pnas.0803341105, 2448841, 18550825.
129. Ristich V, Liang S, Zhang W, Wu J, Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005, 35:1133-1142. 10.1002/eji.200425741, 15770701.
130. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005, 19:662-664.
131. Mandelboim O, Reyburn HT, Vales-Gomez M, Pazmany L, Colonna M, Borsellino G, Strominger JL. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 1996, 184:913-922. 10.1084/jem.184.3.913, 2192787, 9064351.
132. Falk CS, Steinle A, Schendel DJ. Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells. J Exp Med 1995, 182:1005-1018. 10.1084/jem.182.4.1005, 2192283, 7561674.
133. Morel E, Bellon T. HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j. J Immunol 2008, 181:2368-2381.
134. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004, 5:1260-1265. 10.1038/ni1138, 15531883.
135. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002, 3:83-90.
136. Dietrich J, Cella M, Colonna M. Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol 2001, 166:2514-2521.
137. HoWangYin KY, Caumartin J, Favier B, Daouya M, Yaghi L, Carosella ED, LeMaoult J. Proper regrafting of Ig-like transcript 2 after trogocytosis allows a functional cell-cell transfer of sensitivity. J Immunol 2011, 186:2210-2218. 10.4049/jimmunol.1000547, 21242521.
138. Le Rond S, Azema C, Krawice-Radanne I, Durrbach A, Guettier C, Carosella ED, Rouas-Freiss N. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. J Immunol 2006, 176:3266-3276.
139. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004, 172:834-842.
140. Huang JF, Yang Y, Sepulveda H, Shi W, Hwang I, Peterson PA, Jackson MR, Sprent J, Cai Z. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science 1999, 286:952-954. 10.1126/science.286.5441.952, 10542149.
141. Cox JH, McMichael AJ, Screaton GR, Xu XN. CTLs target Th cells that acquire bystander MHC class I-peptide complex from APCs. J Immunol 2007, 179:830-836.
142. Hwang I, Huang JF, Kishimoto H, Brunmark A, Peterson PA, Jackson MR, Surh CD, Cai Z, Sprent J. T cells can use either T cell receptor or CD28 receptors to absorb and internalize cell surface molecules derived from antigen-presenting cells. J Exp Med 2000, 191:1137-1148. 10.1084/jem.191.7.1137, 2193171, 10748232.
143. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007, 109:2040-2048. 10.1182/blood-2006-05-024547, 17077329.
144. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci U S A 2004, 101:7064-7069. 10.1073/pnas.0401922101, 406466, 15103024.
145. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003, 33:125-134. 10.1002/immu.200390015, 12594841.
146. Puppo F, Contini P, Ghio M, Indiveri F. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction. ScientificWorldJournal 2002, 2:421-423.
147. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999, 189:1093-1100. 10.1084/jem.189.7.1093, 2193010, 10190900.
148. Jinushi M, Takehara T, Tatsumi T, Kanto T, Miyagi T, Suzuki T, Kanazawa Y, Hiramatsu N, Hayashi N. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 2004, 173:6072-6081.